A nested set of 11 overlapping synthetic peptides covering the entire sequence of rubella virus capsid protein was synthesized, purified, and tested against human rubella virus-specific T-cell lines and rubella virusseropositive sera. T-cell lines derived from four donors responded strongly to four synthetic peptides containing residues 96 to 123, 119 to 152, 205 to 233, and 255 to 280. Only one peptide (residues 255 to 280) was recognized by all four T-cell lines. Two human immunodominant linear B-cell epitopes were mapped to residues 1 to 30 and 96 to 123 by using peptide-specific enzyme-linked immunosorbent assay. All 11 synthetic peptides were highly immunogenic and induced strong antibody responses in rabbits against the respective immunized peptides. Seven of the 11 rabbit antipeptide antisera (anti-1-30, -74-100, -96-123, -119-152, -205-233, -231-257, and -255-280) specifically recognized the capsid protein on immunoblots. Identification of these Tand B-cell epitopes represents the first step toward rational design of synthetic vaccines against rubella.
Rubella is usually a benign childhood infection, but rubella virus (RV) can cause a persistent infection of the brain called progressive rubella panencephalitis (53) . RV has been isolated from peripheral blood lymphocytes of women with rubella-associated arthritis (7) and from synovial cells of patients with juvenile rheumatoid arthritis (15) . Minor antigenic differences have been observed between wild-type and vaccine strains of RV (22) . These differences may be responsible for the high rate of reinfections in individuals with vaccine-induced rather than natural immunity to rubella (33, 49) . In addition to these problems, RV grows to relatively low titer and its structural proteins are difficult to purify. Therefore, it is clear that a new approach is required to design a safer and effective rubella vaccine, especially for susceptible pregnant women. Efforts have recently focused on characterizing both the viral genome and the host immune responses.
RV is the sole member of the genus Rubivirus in the family Togaviridae (30) . The primary sequences of the RV structural proteins decoded from the cDNA clones have been reported (9) . The RV virion contains an RNA genome enclosed within an icosahedral capsid composed of multiple copies of a basic capsid (C) protein of 33 kDa (39) . Surrounding this nucleocapsid is a lipid bilayer in which viral glycoproteins El (58 kDa) and E2 (42 to 47 kDa) are embedded (39) . Glycoprotein El has been shown to contain hemagglutinin and virus neutralization epitopes (52) . E2-specific antibodies are capable of neutralizing viral infection in vitro (18) . Studies have been carried out to characterize the specificity of the antibody response against rubella. A rubella-specific immunoglobulin M (IgM) response is widely used for diagnosis of recent RV infection (20) , and the production of rubella-specific IgA antibodies has been shown to be important in the prevention of reinfection (20) . Much of the rubella-specific IgM reacts with the El protein, while most of the IgA reacts with the C protein (43) . IgG antibody response can be elicited by all of the structural proteins (43) .
Little is known about the cellular immune response to RV * Corresponding author.
structural proteins, although both T-helper cell proliferation (3, 24, 29, 51) and cytolytic T-lymphocyte responses (48) can be measured during viral infections. An understanding of the humoral and cellular immune responses may lead to development of a safe and effective rubella vaccine. In this study, we attempt to define human T-and B-cell epitopes of the C protein of RV, using 11 overlapping synthetic peptides covering its entire sequence (9) .
MATERIALS AND METHODS
Virus. RV strain M33 (ATCC VR-315) was grown in Vero cells and isolated from the culture supernatant as described previously (9) . The virus pellets were suspended in a small volume of phosphate-buffered saline (PBS) and stored at -70°C. The virus stock was titrated in RK 13 cells, using an immunocytochemical focus assay modified from methods described elsewhere (16, 40, 52) . The virus stock (5 x 107 focus-forming units/ml) was inactivated by UV light (254 nm; model UVG-54; UV Products Inc.) for 10 min before use.
Peptide synthesis. Peptides were synthesized in an automated ABI 430A peptide synthesizer, using solid-phase methods (32) . Eleven peptides (27 to 34 residues in length) covering the entire sequence of RV C protein were synthesized. In some peptides, an additional cysteine residue was added at the C terminus for coupling to a carrier. Synthetic peptides were cleaved from the resin by treatment with hydrogen fluoride and purified by reverse-phase high-pressure liquid chromatography using a Vydac C4 column. The purity of all peptide preparations exceeded 95%. For Bio-Rad), and the relative density of bands was determined by the integration of the area of absorbance peaks. RESULTS Selection of peptides. To map the T-and B-cell immunodominant epitopes of RV C protein as a basis for the rational design of a synthetic peptide-based rubella vaccine, we synthesized 11 overlapping peptides covering the entire C-protein sequence. The lengths of the peptides were chosen on the basis of the high index of hydrophilic e turns, as judged by secondary-structure prediction analysis according to Chou and Fasman (8) and Hopp and Woods (21) (Fig. 1 ). These regions are likely to be exposed at the surface and antigenic for B cells. T-cell antigenic sites are postulated to be amphipathic helices with one face predominantly polar and the opposite face predominantly apolar (28) . Although antigenicity prediction methods are popular for predicting the locations of virus epitopes, there is evidence that none of the methods achieves a high level of correct prediction. Most workers have used fairly long peptides to search for continuous epitopes in proteins replete with antigenically active regions. In the present studies, long peptides (>25 residues) were synthesized to mimic epitopes on native capsid protein because they have more chance of having a conformation similar to that of the corresponding portion of the native antigen (50) . An additional cysteine residue was added to the C-terminal end of peptides Cl, C3, C4, C5, C10, and Cll for later conjugation.
T-cell response to C peptides. Sera and PBMC were isolated from seven healthy donors. Six of the seven donors were shown to be seropositive to RV structural proteins in immunoblot analysis using nonreducing conditions (Fig. 2 ).
Four positive sera (MS, AT, RM, and DO) reacted strongly with the C protein. Lymphocyte proliferative responses of human PBMC were determined in vitro by direct stimulation with RV or with increasing doses of the C peptides. PBMC from all six seropositive donors showed significant proliferative response to RV, but weak responses were observed when synthetic peptides were used as stimulating antigens in the fresh PBMC cell proliferative assay (data not shown). One (17, 47) and probed with peptide-specific rabbit antisera raised against individual C peptides. All peptides were recognized by their respective antipeptide antisera. Reactive titers were >1/1,600 (Table 2 ). These results establish that all synthetic peptides are adsorbed to the microtiter plates and their antigenic determinants are accessible to antibody interaction. To address the possibility of nonspecific binding between the synthetic peptides and antibodies, synthetic peptides were screened with normal IgGs from rabbits. No nonspecific binding was found.
It was also of interest to determine human B-cell epitopes of RV C protein. To this end, the synthetic peptides were tested against human RV-positive sera (Table 3) . A representative peptide ELISA reactivity is shown in Fig. 4 . Sera from all six donors were found to react with peptides Cl and C5. In addition, peptides C4, C8, and C6 reacted with sera from CM and DO, CM and MS, and AT, respectively. It is likely that the immunodominant linear B-cell epitopes of RV C protein are located within residues 1 to 30 (Cl) and 96 to 123 (C5). Interestingly, sera of both RM and MS that recognized C protein in immunoblot analysis were found to react weakly with C peptides in the peptide-specific ELISA ( Fig. 2 and Table 3 ). These antibodies might recognize the epitopes that cannot be mimicked by synthetic peptides.
The antigenicity of the synthetic peptides was further assessed by mouse and rabbit antisera raised against C b Immunoblot analysis was carried out with rabbit antisera at a 1:100 dilution (Fig. 4) . Values represent relative density of the C-protein band in optical density units per millimeter as measured by densitometric tracing. SDS-PAGE was carried out under nonreducing and reducing conditions. protein or RV. Mouse and rabbit antisera had previously shown to be RV specific, as judged by both ELISA and immunoprecipitation (27) . Peptides Cl, C3, and C5 reacted strongly with the mouse antisera (Fig. 5A ). These peptides represent mouse immunodominant linear B-cell epitopes. Peptides C6 and C9 reacted weakly with the mouse antisera and may be minor B-cell determinants in mouse. Synthetic peptides C5 and C6 were found to be the major B-cell epitopes when the panel of C peptides were screened with rabbit antisera raised against RV particles (Fig. SB) . Peptides Cl, C4, C7, C9, and Cll were also recognized by rabbit anti-RV serum.
Immunogenicity of the C peptides in rabbits. The capacity of C peptides to elicit peptide-specific antibody production was examined by immunizing rabbits with individual synthetic peptides emulsified in Freund's complete adjuvant. After three doses (100 ,ug per injection), IgG antibody responses were tested by using peptide-specific ELISAs. All sera with C protein were investigated by immunoblot analysis. Purified RV was subjected to SDS-PAGE, and individual viral proteins were electrotransferred to a nitrocellulose membrane. It is worthwhile to point out that under nonreducing conditions (Fig. 6A) , C protein migrated as a disulfide-linked dimer of molecular mass 65 kDa (44) . Seven of the peptide-specific antisera (anti-Cl, -C4, -C5, -C6, -C9, -C10, and -Cl1) recognized C protein in the western immunoblots under both reducing and nonreducing conditions (Fig. 6) . Under reducing conditions, anti-Cl peptide serum exhibited the strongest response (Fig. 6B) , whereas anti-C5 and -C6 sera reacted better with the dimeric form of C protein (Fig. 6A) . The reactivities of these peptide antisera with C protein under both reducing and nonreducing conditions suggest that the B-cell epitopes are not dependent on conformation and are probably exposed on the protein surface ( Fig. 6 and Table 2 ).
DISCUSSION
Several live, attenuated rubella vaccines have been introduced since 1969 (42) . Immunization of infants and susceptible women of child-bearing age against rubella is now a standard public health measure. However, there are still major medical concerns: the reinfection of vaccinees by wild-type RV and the risk of both congenital infection of the fetus and of rubella-associated arthritis arising from vaccination (46) . There is a clear requirement for the development of a noninfectious rubella vaccine, for example by genetic manipulation and synthetic methods. Recent Anticapsid antibodies are found in the majority of individuals exposed to RV (11, 44) . In this study, human, rabbit, and mouse sera reacted strongly with residues 1 to 30 (Cl) and 96 to 123 (C5). Thus, these two regions contain the immunodominant linear B-cell epitopes. No relationship between T-and B-cell responses to peptides is obvious. T-cell lines derived from donors MS and TZ did not respond to C peptides, whereas their sera reacted with peptides Cl and C5. These specific B-cell responses might be induced or helped by the specific T cells whose epitopes were located in other parts of the RV protein than the capsid. Milich et al. (36) found that hepatitis B verus (HBV) core antigen-specific helper T cells could help B cells to produce antibody against both envelope HBV surface and core antigens, even though these antigens were on separate molecules. Recently, an HBV immunogen composed of nucleocapsid T-cell sites and envelope B-cell epitopes has been constructed and shown to be involved in both T-and B-cell responses relevant to the native antigen (35) .
T-helper cells participate in the protective immune response by enhancing the production of virus-neutralizing antibodies by B cells, producing lymphokines such as gamma interferon that directly inhibit viral replication and killing infected cells that coexpress viral antigen and major histocompatibility complex (MHC) class II antigens. Although it is known that both T-helper cell proliferation and cytolytic T-lymphocyte responses can be measured during RV infections (3, 24, 29, 51, 53) , the exact role of T-helper cells in elimination of RV has not been totally elucidated because of lack of a good RV-infected animal model. Precise locations of epitopes for each viral protein have not been mapped. Overlapping synthetic peptides have permitted successful identification of the antigenic determinants on C protein capable of stimulating RV-specific human T-cell lines. Of the six human RV-specific T-cell lines derived from donors, AT responded to four synthetic peptides (C5, C6, C9, and Cll), RM responded to three peptides (C5, C6, and Cll), and CM and DO responded only to Cll. Cell lines derived from MS and TZ recognized no C peptides. It is possible that T-cell epitopes for these cell lines (MS and TZ) are not contained only within the 11 synthetic peptides. Surface marker analysis by FACS showed that most cells in the lines studied here were CD4+ T-helper cells. The response appeared to be MHC class II restricted, but four donors recognized one immunodominant epitope Cll (residues 255 to 280). This finding is consistent with the results of studies of the T-cell proliferative response to HBV, herpes simplex virus, and influenza virus (2, 12, 37) . The role of MHC class II-restricted RV-specific T-cells in RV infection and protection is unknown. A low RV antigen-specific response was shown to be associated with HLA-DW2 (23) . The HLA restriction pattern and the relationship of HLA phenotype to T-cell response needs study, as it has been reported that particular HLA phenotypes are immunologically nonresponsive to rubella vaccines and RV infection (23) (24) (25) . The HLA DR phenotypes of the four individuals (AT, RM, CM, and DO) whose T-cell lines responded to C peptides of RV are 4,7; w9,w53; 1,4,w53; and w9,w53, respectively. We have isolated several T-cell clones specific to peptide C6, C9, Cll from two of them (RM and AT).
Preliminary observation of these T-cell clones indicated that recognition of some of these epitopes is associated with HLA-DRw9 or HLA-DR4 (unpublished data).
Recently, two models have been proposed to identify regions of antigens involved in T-cell recognition. Delisi and Berzofsky have found that a large proportion of T lymphocytes appear to react with a-helical amphipathic regions within the amino acid sequence of the antigen (13) . On the other hand, the studies of Rothbard and Taylor point to the existence of a four-to five-amino-acid sequence motif in a large number of T-cell antigenic determinants (45) . This motif is composed of either a glycine or a charged amino acid residue in the first position, then two or three hydrophobic residues, and either a glycine, a polar, or a charged residue in the last position. Interestingly, none of the identified human T-cell epitopes were predicted as potential T-cell determinants by the amphipathicity algorithm of Delisi and Berzofsky (13) . However, these human T-cell epitopes contain one or more T-cell-binding motifs as predicted by Rothbard and Taylor (45) (Fig. 7) .
Short synthetic peptides representing B-cell epitopes are generally poor immunogens and need to be coupled to a carrier protein with T-helper cell epitopes in order to induce an antibody response. However, such an approach has limited relevance to vaccine development because of the phenomenon of carrier-induced suppression and the failure to induce priming of a T-cell memory response to the pathogen. Thus, to design a synthetic peptide vaccine, it is necessary to synthesize defined immunogens composing relevant T-and B-cell epitopes. In this study, we were interested in determining whether long peptides containing a high index of hydrophilic 1 turns, as predicted by secondary structure analysis, could be used as immunogens. Since the minimum length of a T-cell epitope is 8 to 12 amino acids and 6 to 10 residues are required for a B-cell epitope (14, 45) , peptides with more than 25 residues were synthesized and tested for immunogenicity. In addition, these peptides were used in the search for functional T-cell epitopes that have not been identified by the human RV-specific T-cell lines because of the limits imposed on T-cell antigen recognition by MHC restriction. All 11 synthetic peptides were highly immunogenic and induced strong antibody responses in rabbits, as judged by the peptide-specific ELISA (Table 2) . These results are also consistent with reports by Lerner and collaborators, who suggest that antibodies can be raised against almost any part of a protein by using synthetic peptides as immunogens (26) . Cross-reactions of peptidespecific antisera with C protein were demonstrated by immunoblot analysis. Seven of the peptide-specific antisera (anti-Cl, -C4, -C5, -C6, -C9, -C10, and -C11) recognized C protein in western blots under both reducing and nonreducing conditions (Fig. 6) . The high-affinity binding suggests that these B-cell epitopes are not restricted to disulfide bridge formation and are most likely surface exposed. This finding is consistent with the study reported by Green et 
